Clinical trial NCT06822907: Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults
Official title: Immunogenicity and Safety of the 20-Valent Pneumococcal Conjugate Vaccine (PCV-20) Administered During an Acute Febrile Illness in Adults: a Multicentric Randomized Non-inferiority Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Acute Febrile Illness
Pneumococcal Infections
Keywords: vaccin
pneumococcal
Prevenar 20
Acute febrile illness
infections
PCV-20
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
Collaborators: name: Ministry of Health, France
First posted: 2025-02-12
Enrollment: 1052
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Prospective Randomised Open Blinded End-point trial (PROBE) Non inferiority design
Primary purpose: PREVENTION

Brief summary: Streptococcus pneumoniae is responsible for serious infections associated to numerous hospitalizations and high rate of mortality. The incidence and therefore the burden of pneumococcal infections have been significantly reduced thanks to the use of pneumococcal conjugate vaccines (PCVs). PCVs were shown to be effective against vaccine-type serotypes causing both non-invasive and invasive pneumococcal diseases (IPD) in children and adults. PCVs use in children was shown to have an impact on IPD incidence among adults due to herd immunity and on antimicrobial resistance. To increase the protection of at-risk patients against IPD, the 20-valent PCV (PCV-20) is recently recommended in adults, after a period where PCV-13 followed by pneumococcal polysaccharide vaccine 23 valent (PPV-23) was recommended. PCV-20 effectiveness against IPD and against pneumonia was inferred from immunobridging with PCV-13. Indeed PCV-13 was shown effective to reduce the incidence of low respiratory tract infections and IPD (bacteraemia and meningitis) in 65-years-old-adults and older. Currently immunization against S. pneumoniae is recommended with PCV-20 for adult patients at-risk for IPD such as immunocompromised (=high-risk patients) and in immunocompetent people with underlying chronic conditions (cardiovascular, liver, pulmonary, kidney diseases and diabetes mellitus) (=medium risk patients). However, vaccine coverage against IPD in adults remains low globally, and does not exceed 5 % in France. Reducing missed opportunities of vaccination for S. pneumoniae is crucial.

Detailed description: Patients at-risk of IPD are very frequently hospitalized for acute febrile illnesses. More than 50 % of the IPD at-risk patients hospitalized for an IPD or a pneumonia have been admitted to the hospital during the past 5 years without receiving a pneumococcal vaccination. Hospitalization appears to be therefore an opportunity to provide vaccines. However, physicians usually consider that vaccines should be postponed during an acute febrile illness including if non-severe. This consideration of not vaccinating during an acute febrile illness is however not evidence-based. This is associated to concerns about a potential risk of an impaired response to the vaccine and safety. In children, data about vaccination during a febrile illness have shown no safety nor efficacy concerns. In most countries, recommendations regarding this particular point are unclear.

In fine, vaccination is then rarely provided during the hospital stay as well as after discharge including in the USA, a country where it is recommended to vaccinate whatever the body temperature is and during hospitalization. Reluctance to immunize adults in this situation is probably due to the absence of evidence showing that it is as effective and safe as vaccinating patients without an acute or febrile illness.

To reduce the number of missed opportunities to immunize adults against S. pneumoniae, investigators aim to demonstrate that the administration of PCV-20 during an acute non-severe febrile illness is non-inferior than the administration one month after fever resolution in terms of immunogenicity (assessed by vaccine types (VT) Immunoglobulin G (IgG) concentrations and at least 2-fold change increase), and that it is as safe.

Eligibility criteria: Inclusion criteria :

* History of body temperature ≥ 38°C measured at least twice prior to randomization (Randomization must be performed as soon as possible on a febrile patient or 72 hours after apyrexia at the latest)
* Having at least one comorbidity that defines patients as medium or high risk for pneumococcal invasive infection:

  * Medium risk: Cyanogenic congenital heart disease; chronic heart failure; chronic respiratory failure; chronic obstructive pulmonary disease; emphysema; severe asthma under chronic treatment; chronic renal failure; chronic liver disease; diabetes mellitus treated; Osteo-meningeal leak or cochlear implant.
  * High risk : Hypo or asplenic people; hereditary immunodeficiency syndromes; people living with HIV; solid organ transplanted; People under immunosuppressors (corticosteroids, biotherapy) for an auto-immune or an inflammatory chronic disease; patients with nephrotic syndrome
* Hospitalization for \> 24 hours long
* Social security affiliation
* Signed informed consent

Exclusion criteria :

* Patient unable to give informed consent
* Curators, wardship
* History of previous vaccination with PCV-7 or PCV-13 or PCV-20
* History of PPV-23 in the previous year
* Patient having received another vaccination within one month prior to inclusion or planning another vaccination in the month after inclusion except for Influenza vaccine.
* Patient with history of bone marrow transplantation
* Patient with haematological malignancies
* Patient under chemotherapy for solid tumor or with a history of chemotherapy in the past three months
* Patient treated with Rituximab currently or in the past 6 months
* Patient with Sequential Organ Failure Assessment (qSOFA ) score ≥ 2 at randomization (acute severe febrile illness)
* Patient hospitalized in an Intensive Care Unit
* Pregnancy
* Breastfeeding woman
* Recipients of polyclonal gammaglobulins in the past three months
* Inability to follow the protocol
* Bleeding disorder contra-indicating intramuscular injection according to the investigator
* History of allergy to PCV-20 or vaccine-related components.
* S. pneumoniae infection with laboratory confirmation (blood culture, culture from a sterile site, urinary or Cerebrospinal fluid antigens, sputum culture with \> 10\^7 colony forming unit (CFU)/mL) being the cause of the current hospitalization

Primary outcomes:
measure: Proportion of immune "good responders" to PCV-20 in both arms
timeFrame: 1 month post vaccination
Secondary outcomes:
measure: Safety endpoints in both arms in the month following vaccination : adverse events
timeFrame: 1 month post vaccination
measure: Frequency of local reactions
timeFrame: 1 month post vaccination
measure: Frequency of systemic events related to the vaccination
timeFrame: 1 month post vaccination
measure: Proportion of immune good responders serotype by serotype
timeFrame: 1 month post vaccination
measure: opsonophagocytic activity (OPA) IgG titers for serotype by serotype
timeFrame: 1 month post vaccination
measure: Proportion of the participants immune "good responders" to PCV-20 in both arms.
timeFrame: 1 year post vaccination
measure: Number of low respiratory tract infections events
timeFrame: 1 year post vaccination
measure: Number of confirmed S.pneumoniae infections
timeFrame: 1 year post vaccination
measure: Analyze the gut microbiota on the immune response
timeFrame: 1 year post vaccination
measure: Reactogenic inflammatory response after vaccination
timeFrame: 1 month post vaccination
measure: Frequency of specific PCV-20 interferon-gamma (IFNg) secreting CD4 or CD8 T cells
timeFrame: 1 month post vaccination
measure: Frequency of specific PCV-20 IFNg secreting CD4 or CD8 T cells
timeFrame: 1 year post vaccination
measure: Proportion of volunteers with circulatory immunoglobulin A (IgA)
timeFrame: 1 month post vaccination
Other outcomes:
Locations:
city: Annecy
country: France
facility: Centre Hospitalier
city: Bordeaux
country: France
facility: Centre Hospitalier
city: Brest
country: France
facility: Centre Hospitalier Universitaire
city: Brest
country: France
facility: Centre Hospitalier
city: Chambéry
country: France
facility: Centre Hospitalier General Metropole Savoie
city: Créteil
country: France
facility: Centre Hospitalier de Creteil
city: Dijon
country: France
facility: Centre Hospitalier Universitaire
city: Grenoble
country: France
facility: Centre Hospitalier Universitaire
city: La Roche-sur-Yon
country: France
facility: Centre Hospitalier
city: Le Mans
country: France
facility: Centre Hospitalier General
city: Lille
country: France
facility: Centre Hospitalier Universitaire
city: Lyon
country: France
facility: Hospices Civils de Lyon
city: Montpellier
country: France
facility: Centre Hospitalier Regional Universitaire
city: Nancy
country: France
facility: Centre Hospitalier Universitaire
city: Nantes
country: France
facility: Centre Hospitalier Universitaire
city: Nice
country: France
facility: Centre Hospitalier Universitaire
city: Nîmes
country: France
facility: Centre Hospitalier Universitaire
city: Paris
country: France
facility: Centre Hospitalier Bichat
city: Paris
country: France
facility: Assistance Publique Hopitaux de Paris
city: Rennes
country: France
facility: Centre Hospitalier Universitaire
city: Rouen
country: France
facility: Centre Hospitalier Universitaire
city: Saint-etienne
country: France
facility: CHU de Saint-Etienne
Study officials:
affiliation: CHU SAINT-ETIENNE
name: Elisabeth BOTELHO-NEVERS, MD PhD
role: PRINCIPAL_INVESTIGATOR
References: